These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 33990536

  • 1. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
    Luo M, Xiong Y, Lin Y, Liang R, Li Y, Ge L.
    Med Sci Monit; 2021 May 15; 27():e930215. PubMed ID: 33990536
    [Abstract] [Full Text] [Related]

  • 2. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.
    Wang J, Yang K, Yang X, Jin T, Tian Y, Dai C, Xu F.
    Mol Carcinog; 2024 Jul 15; 63(7):1275-1287. PubMed ID: 38578157
    [Abstract] [Full Text] [Related]

  • 3. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F, Cai D.
    Gene; 2022 Jan 10; 807():145964. PubMed ID: 34530087
    [Abstract] [Full Text] [Related]

  • 4. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines.
    Wang XK, Liao XW, Yang CK, Liu ZQ, Han QF, Zhou X, Zhang LB, Deng T, Gong YZ, Huang JL, Huang R, Han CY, Yu TD, Su H, Ye XP, Peng T, Zhu GZ.
    J Cell Physiol; 2020 Oct 10; 235(10):7003-7017. PubMed ID: 32037547
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY, Zhang K, Chen DQ, Chen J, Feng B, Song H, Chen Y, Zhu Z, Lu L, De W, Wang R, Chen LB.
    Oncotarget; 2015 Jul 30; 6(21):18613-30. PubMed ID: 26164082
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73.
    Zhao J, Xu T, Wang F, Cai W, Chen L.
    Biomed Pharmacother; 2017 Jun 30; 90():744-751. PubMed ID: 28419971
    [Abstract] [Full Text] [Related]

  • 9. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K, Dou C, Zheng X, Li C, Yang W, Yao Y, Liu Q.
    BMC Cancer; 2014 Dec 12; 14():938. PubMed ID: 25494879
    [Abstract] [Full Text] [Related]

  • 10. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH, Niu H, Li Z, Huo RT, Wang JM, Liu J.
    Cancer Biomark; 2018 Dec 12; 23(1):33-43. PubMed ID: 29991125
    [Abstract] [Full Text] [Related]

  • 11. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
    Wang B, Fang J, Qu L, Cao Z, Zhou J, Deng B.
    Tumour Biol; 2015 Sep 12; 36(9):6901-8. PubMed ID: 25851347
    [Abstract] [Full Text] [Related]

  • 12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S.
    Oncotarget; 2015 Dec 01; 6(38):41383-97. PubMed ID: 26515591
    [Abstract] [Full Text] [Related]

  • 13. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
    Li L, Han T, Liu K, Lei CG, Wang ZC, Shi GJ.
    Eur Rev Med Pharmacol Sci; 2019 Jun 01; 23(12):5392-5401. PubMed ID: 31298392
    [Abstract] [Full Text] [Related]

  • 14. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.
    Xu L, Feng X, Hao X, Wang P, Zhang Y, Zheng X, Li L, Ren S, Zhang M, Xu M.
    J Exp Clin Cancer Res; 2019 Feb 22; 38(1):98. PubMed ID: 30795787
    [Abstract] [Full Text] [Related]

  • 15. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 22; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.
    Wang K, Liang Q, Wei L, Zhang W, Zhu P.
    Tumour Biol; 2016 Mar 22; 37(3):3823-30. PubMed ID: 26474589
    [Abstract] [Full Text] [Related]

  • 17. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
    Chen D, Chen W, Xu Y, Zhu M, Xiao Y, Shen Y, Zhu S, Cao C, Xu X.
    J Med Genet; 2019 Jan 22; 56(1):43-49. PubMed ID: 29967134
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
    Xing Y, Liu Y, Qi Z, Liu Z, Wang X, Zhang H.
    Cell Mol Biol Lett; 2021 Nov 27; 26(1):49. PubMed ID: 34837962
    [Abstract] [Full Text] [Related]

  • 20. miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7.
    Liu X, Li J, Yu Z, Li J, Sun R, Kan Q.
    Oncol Res; 2017 Mar 13; 25(3):427-435. PubMed ID: 27697092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.